TABLE 3.
Overall survival by subgroups.
| Population | Median OS (95%CI) months | Mean ± SD 12 months OS % | p Value |
|---|---|---|---|
| Overall | 4.2 (3.1–5.6) | 2.4 ± 0.3 | |
| RR status | |||
| Refractory | 3.9 (2.9–5.3) | 20.4 ± 4.2 | 0.6 |
| Relapsed | 4.6 (3.0–6.7) | 27.8 ± 4.7 | |
| Treatment | |||
| ICT | 5.6 (3.6–8.4) | 31.8 ± 4.9 | 0.01 |
| AZA | 6.6 (4.5–8.4) | 29.4 ± 7.8 | |
| BSC | 1.8 (1.0–2.8) | 9.8 ± 3.8 | |
| Treatment refractory | |||
| ICT | 5.6 (3.6–8.8) | 11.1 ± 6.0 | 0.01 |
| AZA | 3.9 (0.4–7.0) | 0 | |
| BSC | 1.4 (0.9–3.9) | 0 | |
| Treatment relapsed | |||
| ICT | 4.6 (2.7–13.8) | 40.0 ± 8.9 | 0.002 |
| AZA | 6.7 (4.8–12.6) | 38.5 ± 9.5 | |
| BSC | 1.8 (0.9–3.1) | 8.8 ± 4.9 | |
Abbreviations: ICT, intensive chemotherapy; AZA, azacitidine; BSC, best supportive care; OS, overall survival; SD, standard deviation; R/R, relapsed or refractory.